SYRACUSE BIOPHARMA

Syracuse Biopharma was formed in 2017 by Eureka Therapeutics to commercialize Eurekaโ€™s proprietary TCR-mimic and antibody-TCR ARTEMISยฎ programs in China and the ASEAN countries. Syracuseโ€™s clinical programs include Eurekaโ€™s anti-AFP ARTEMISยฎ program for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer, which is currently in a Phase I/II clinical trial in the United States.

#More

SYRACUSE BIOPHARMA

Industry:
Biopharma Biotechnology Pharmaceutical

Founded:
2017-01-01

Address:
Hong Kong, Hong Kong Island, Hong Kong

Country:
Hong Kong

Status:
Active


More informations about "Syracuse Biopharma" on Search Engine